Article
Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.
Oncology - 1 Jan 2012
Modest Dominik P, Brodowicz Thomas, Stintzing Sebastian, Jung Andreas, Neumann Jens, Laubender Ruediger P, Ocvirk Janja, Kurteva Galina, Papai Zsuzsanna, Knittelfelder Regina, Kirchner Thomas, Heinemann Volker, Zielinski Christoph C
Abstract excerpt
PURPOSE: This study investigated the impact of specific mutations in codon 12 of the Kirsten-ras (KRAS) gene on treatment efficacy in patients with metastatic colorectal cancer (mCRC). PATIENTS: Overall, 119 patients bearing a KRAS mutation in codon 12 were evaluated. All patients received cetuximab-based first-line chemotherapy within the Central European Cooperative Oncology Group (CECOG), AIO KRK-0104 or AIO...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.